Posted by Michael Wonder on 24 Jul 2023
Astria Therapeutics receives fast track designation for STAR-0215 for the treatment of hereditary angioedema
20 July 2023 - On track for proof of concept results in HAE patients in mid 2024.
Astria Therapeutics today announced that the STAR-0215 development program has received fast track designation from the US FDA for the treatment of hereditary angioedema.
